H-1B sponsorPAFEIN 55-0455423Updated Jun 2026
Mylan Pharmaceuticals, Inc.
US H-1B Labor Condition Application activity for Mylan Pharmaceuticals, Inc.. Filed 132 disclosures between FY2010 and FY2025 from worksites with a PA headquarters indicator.
Total filings
3
Outside top-N · FY2025
Certified
66.7%
unconditional · FY2025
Withdrawn
33.3%
withdrawn rate · FY2025
Denied
0.0%
rejection rate · FY2025
Outcome breakdown
Share of Mylan Pharmaceuticals, Inc.’s LCAs by DOL case status, all fiscal years. Use the year filter above for a single-year breakdown.
Certified83.3%
Withdrawn16.7%
Top occupations sponsored
SOC codes filed most by Mylan Pharmaceuticals, Inc. across all fiscal years. Click any row to open the national salary guide.
| # | SOC | Title | Filings |
|---|---|---|---|
| 1 | 19-2031 | Chemists | 30 |
| 2 | 19-1042 | Medical Scientists, Except Epidemiologists | 24 |
| 3 | 15-1252 | Software Developers | 15 |
| 4 | 17-2112 | Industrial Engineers | 9 |
| 5 | 17-2141 | Mechanical Engineers | 6 |
| 6 | 15-2041 | Statisticians | 5 |
| 7 | 13-1041 | Compliance Officers | 5 |
| 8 | 19-1022 | Microbiologists | 4 |
| 9 | 15-1299 | Computer Occupations, All Other | 4 |
| 10 | 11-3021 | Computer and Information Systems Managers | 3 |
Chemists
30
Medical Scientists, Except Epidemiologists
24
Software Developers
15
Industrial Engineers
9
Mechanical Engineers
6
Statisticians
5
Compliance Officers
5
Microbiologists
4
Computer Occupations, All Other
4
Computer and Information Systems Managers
3
Filings by fiscal year
Year-over-year H-1B filing volume — a hiring-demand signal, not headcount.
| Year | Filings |
|---|---|
| FY2010 | 4 |
| FY2011 | 11 |
| FY2012 | 6 |
| FY2013 | 14 |
| FY2014 | 17 |
| FY2015 | 14 |
| FY2016 | 20 |
| FY2017 | 12 |
| FY2018 | 15 |
| FY2019 | 13 |
| FY2021 | 1 |
| FY2023 | 1 |
| FY2024 | 1 |
| FY2025 | 3 |
Compare Mylan Pharmaceuticals, Inc. with another sponsor
Side-by-side view of KPIs, outcomes, top breakdowns and yearly trend.
Explore by rank
Pre-built leaderboards for the most-asked questions.